wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q34180815-653AF5E1-FDA6-43A2-9307-777CF2C5722B
Q34180815-653AF5E1-FDA6-43A2-9307-777CF2C5722B
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34180815-653AF5E1-FDA6-43A2-9307-777CF2C5722B
A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.
P2860
Q34180815-653AF5E1-FDA6-43A2-9307-777CF2C5722B
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34180815-653AF5E1-FDA6-43A2-9307-777CF2C5722B
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
69f22748e8aaac97638edd18e03b41d1bc2b8755
P2860
ERBB receptors and cancer: the complexity of targeted inhibitors